Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 May 23:JCO2018789636. doi: 10.1200/JCO.2018.78.9636. [Epub ahead of print]

PMID:
29791286
2.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
3.

Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.

Solomon BL, Garrido-Laguna I.

Future Oncol. 2018 Apr;14(10):947-962. doi: 10.2217/fon-2017-0597. Epub 2018 Mar 15.

PMID:
29542354
4.

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.

Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S.

ESMO Open. 2018 Jan 27;3(1):e000282. doi: 10.1136/esmoopen-2017-000282. eCollection 2018.

5.

Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis.

Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R.

Ann Surg Oncol. 2017 Dec;24(13):4001-4008. doi: 10.1245/s10434-017-6131-9. Epub 2017 Oct 17.

PMID:
29043526
6.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.

7.

Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.

Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I.

Immunotherapy. 2017 Sep;9(10):797-804. doi: 10.2217/imt-2017-0042.

PMID:
28877632
8.

Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Au TH, Wang K, Stenehjem D, Garrido-Laguna I.

J Gastrointest Oncol. 2017 Jun;8(3):387-404. doi: 10.21037/jgo.2017.01.04. Review.

9.

Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.

Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM.

Cancer. 2017 Oct 1;123(19):3816-3824. doi: 10.1002/cncr.30780. Epub 2017 Jun 16.

PMID:
28621885
10.

A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency.

Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ.

ACG Case Rep J. 2017 Mar 1;4:e34. doi: 10.14309/crj.2017.34. eCollection 2017.

11.

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F.

Oncotarget. 2016 Oct 11;7(41):67521-67531. doi: 10.18632/oncotarget.11750.

12.

Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue.

Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL.

Clin Neurol Neurosurg. 2016 Oct;149:11-4. doi: 10.1016/j.clineuro.2016.05.023. Epub 2016 Jul 14. No abstract available.

PMID:
27450762
13.

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Epub 2016 Mar 23. Review.

14.

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Patel SB, Gill D, Garrido-Laguna I.

Onco Targets Ther. 2015 Dec 30;9:75-86. doi: 10.2147/OTT.S68558. eCollection 2016. Review.

15.

N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.

Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S.

Oncoscience. 2015 Mar 14;2(3):285-93. eCollection 2015.

16.

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Garrido-Laguna I, Hidalgo M.

Nat Rev Clin Oncol. 2015 Jun;12(6):319-34. doi: 10.1038/nrclinonc.2015.53. Epub 2015 Mar 31. Review.

PMID:
25824606
17.

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2015 Feb;19(103):109-16. Review.

18.

Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2015 Feb;19(103):101-8. Review.

19.

A framework for genomic biomarker actionability and its use in clinical decision making.

Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R.

Oncoscience. 2014 Oct 22;1(10):614-623. eCollection 2014.

20.

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2014 Dec;18(101):331-9. Review.

21.

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2014 Dec;18(101):323-30. Review.

22.

Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.

Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:278-81. doi: 10.1007/s12029-014-9662-3. No abstract available.

PMID:
25367745
23.

Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah.

Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):2078-84.e1-2. doi: 10.1016/j.cgh.2014.04.017. Epub 2014 Apr 24.

PMID:
24768809
24.

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.

Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17.

25.

A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.

Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S.

Invest New Drugs. 2013 Oct;31(5):1257-64. doi: 10.1007/s10637-013-9947-6. Epub 2013 Mar 17.

PMID:
23504398
26.

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.

Oncotarget. 2012 Dec;3(12):1566-75.

27.

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R.

PLoS One. 2012;7(5):e38033. doi: 10.1371/journal.pone.0038033. Epub 2012 May 31.

28.

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R.

Clin Colorectal Cancer. 2012 Dec;11(4):297-303. doi: 10.1016/j.clcc.2012.02.001. Epub 2012 Apr 25.

PMID:
22537607
29.

Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?

Garrido-Laguna I, Janku F.

J Clin Oncol. 2012 Mar 10;30(8):892-3. doi: 10.1200/JCO.2011.40.6538. Epub 2012 Jan 30. No abstract available.

PMID:
22291080
30.

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.

J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.

31.

Novel therapeutic targets in non-small cell lung cancer.

Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R.

J Thorac Oncol. 2011 Sep;6(9):1601-12. doi: 10.1097/JTO.0b013e31822944b3. Review.

32.

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R.

PLoS One. 2011;6(7):e22769. doi: 10.1371/journal.pone.0022769. Epub 2011 Jul 29.

33.

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R.

Cancer. 2012 Mar 1;118(5):1422-8. doi: 10.1002/cncr.26413. Epub 2011 Aug 5.

34.

The inverted pyramid of biomarker-driven trials.

Garrido-Laguna I, Hidalgo M, Kurzrock R.

Nat Rev Clin Oncol. 2011 Aug 2;8(9):562-6. doi: 10.1038/nrclinonc.2011.113. Review.

PMID:
21808269
35.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD.

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.

36.

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M.

Clin Cancer Res. 2011 Sep 1;17(17):5793-800. doi: 10.1158/1078-0432.CCR-11-0341. Epub 2011 Jul 8.

37.

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.

Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D.

Mol Cancer Ther. 2011 Aug;10(8):1311-6. doi: 10.1158/1535-7163.MCT-11-0233. Epub 2011 Jun 14.

38.

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R.

Oncologist. 2011;16(3):327-35. doi: 10.1634/theoncologist.2010-0308. Epub 2011 Feb 21.

39.

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R.

Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.

40.

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M.

Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6.

41.

Response of histiocytoses to imatinib mesylate: fire to ashes.

Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R.

J Clin Oncol. 2010 Nov 1;28(31):e633-6. doi: 10.1200/JCO.2010.29.9073. Epub 2010 Aug 23. No abstract available.

PMID:
20733125
42.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M.

Br J Cancer. 2010 Aug 24;103(5):649-55. doi: 10.1038/sj.bjc.6605819. Epub 2010 Jul 27.

43.

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.

Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R.

Clin Cancer Res. 2010 Aug 1;16(15):4031-7. doi: 10.1158/1078-0432.CCR-10-0672. Epub 2010 Jun 4.

44.

Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.

Garrido-Laguna I, Amador ML, Ruiz J, Cortés-Funes H.

Clin Transl Oncol. 2009 Mar;11(3):183-5.

PMID:
19293057
45.

New scaffolds for the design of selective estrogen receptor modulators.

Martín-Santamaría S, Rodríguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, López-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A.

Org Biomol Chem. 2008 Oct 7;6(19):3486-96. doi: 10.1039/b806918b. Epub 2008 Aug 4.

PMID:
19082149
46.

MRI evaluation of breast cancer.

Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas J.

N Engl J Med. 2007 Jul 12;357(2):191; author reply 193. No abstract available.

47.

Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?

Garrido-Laguna I, Ponz M, Espinós J.

J Clin Oncol. 2007 Mar 20;25(9):1149; author reply 1149-51. No abstract available.

PMID:
17369585

Supplemental Content

Loading ...
Support Center